Hormone replacement therapy and breast cancer morbidity, mortality and recurrence

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 71, Issue 2, 1997, Pages 199-203

  Kenemans, P ^a   Scheele, F ^a   Burger, C W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

breast cancer morbidity; climacteric complaints; hormone replacement therapy

Indexed keywords

ESTROGEN;

ADULT; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CLIMACTERIUM; CONFERENCE PAPER; FEMALE; HORMONE SUBSTITUTION; HUMAN; MORBIDITY; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031080972     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(96)02635-8     Document Type: Conference Paper

References (41)

1. [1] Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517-523.
2. [2] Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995; 142: 788-795.
3. [3] Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995; 141: 828-835.
4. [4] Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992; 117: 1016-1037.
5. [5] Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995; 85: 304-313.
6. [6] Barrell V. The practice of meta-analyses: discussion. Meta-analyses of observational studies: a case study of work in progress. J Clin Epidemol 1995; 48: 165-166.
7. [7] Toniolo PO, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190-197.
8. [8] Wren BG. Hormonal replacement therapy and breast cancer. Eur Menopause J 1995; 2: 13-19.
9. [9] Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effect of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93-100.
10. [10] Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast proliferation and breast cancer risk. Endocr Rev 1993; 15: 17-35.
11. [11] Spicer DV, Pike MC. The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol 1992; 31: 167-174.
12. [12] Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 1991; 151: 67-72.
13. [13] Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc 1991; 265: 1985-1990.
14. [14] Sillero-Arenas M, Delgado Rodriguez M, Ridigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 72: 286-294.
15. [15] Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168: 1473-1480.
16. [16] Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995; 332: 1589-1593.
17. [17] Whitehead M, Lobo RA. Consensus conference: progestagen use in post-menopausal women. Lancet 1988; 2: 1243-1244.
18. [18] Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen - progestin replacement. New Engl J Med 1989b; 321: 293-297.
19. [19] Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C. Combined oestrogen - progestogen replacement and breast cancer risk. Lancet 1992; 340: 1044.
20. [20] Bergkvist L, Adami H-O, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen -progestogen replacement therapy. Am J Epidemiol 1989a; 130: 221-228.
21. [21] Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-142.
22. [22] La Vecchia C, Negri E, Franceschi S et al. Hormone replacement treatment and breast cancer risk: A cooperative Italian study. Br J Cancer 1995; 72: 244-248.
23. [23] Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995; 87: 1067-1071.
24. [24] Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985; 65: 441.
25. [25] Bland KI. Risk factors as an indicator for breast cancer screening in asymptomatic patients. Maturitas 1987; 9: 135-161.
26. [26] Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
27. [27] Dupont WD, Page DL, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989; 63: 948-957.
28. [28] Bright RA, Morrison AS, Brisson J, et al. Histologic and mammographic specificity of risk factors for benign breast disease. Cancer 1989; 64: 653-657.
29. [29] Trapido EJ, Brinton LA, Schairer C, Hoover R. Estrogen replacement therapy and benign breast disease. J Natl Cancer Inst 1984; 73: 1101-1105.
30. [30] Greenberg ER, Barnes AB, Resseguie L, et al. Breast cancer in mothers given diethylstilbestrol in pregnancy. New Engl J Med 1984; 311: 1393-1398.
31. [31] Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen - proggestin replacement therapy among women with a personal history of breast cancer. Menopause: J North Am Menopause Soc 1995; 2: 67-72.
32. [32] DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: A cohort study. Am J Obstet Gynecol 1996; 174: 1494-1498.
33. [33] Stoll BA. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1909-1913.
34. [34] DiSaia PJ. Hormone-replacement therapy in patients with breast cancer: a reappraisal. Cancer 1993; 71: 1490-1500.
35. [35] Marchant DJ. Estrogen-replacement therapy after breast cancer: risks versus benefits. Cancer 1993; 71: 2169-2176.
36. [36] Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372-375.
37. [37] DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG, Creasman WT. Hormone replacement therapy in breast cancer. Lancet 1993; 342: 1232.
38. [38] Lobo RA. Hormone replacement therapy. Oestrogen replacement after treatment for breast cancer? Lancet 1993; 341: 1313-1314.
39. [39] Horn-Ross PL. Multiple primary cancers involving the breast. Epidemiol Rev 1993; 15: 169-176.
40. [40] Kenemans P. Risk profile-based long-term hormone replacement therapy. Eur Menopause J 1995; 2 (4): 3-4.
41. [41] Kenemans P, Barentsen R and Van de Weijer P. Practical HRT. Medicon Europe, Bussum, 1995; 157-158.